Full Text View
Tabular View
No Study Results Posted
Related Studies
Deposition of Inhaled Prolastin in Cystic Fibrosis Patients (CF2)
This study has been completed.
Study NCT00486837   Information provided by Talecris Biotherapeutics
First Received: June 13, 2007   Last Updated: May 7, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis
Additional conditions recognized in this trial
Fibrosis
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
Alpha1-Proteinase Inhibitor (Human)
Additional drug interventions recognized in this trial
Alpha 1-Antitrypsin
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protease Inhibitors
Serine Proteinase Inhibitors
Trypsin Inhibitors
Sponsors listed in this trial
Talecris Biotherapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services